Snakebites still kill in rural Africa due to lack of antivenom

Every year, snakebites claim millions of victims in sub-Saharan Africa, especially in rural areas. Agricultural workers, herders, women gathering firewood, and children are the most exposed, as they often move unprotected in environments where snakes are abundant. These accidents cause severe disabilities, permanent sequelae, or even death, even though they could often be avoided.

Antivenom serum remains the only effective treatment for envenoming, but access to it is extremely limited. In rural areas, health centers are critically short of it, and when it is available, its cost is prohibitive. A vial can cost between $4 and $200, and a full treatment sometimes requires up to eight. For many rural families, these amounts are unaffordable, especially since governments do not cover these expenses in their healthcare systems.

Delays in treatment worsen the situation. Many victims first turn to traditional healers before consulting a doctor, losing precious time. Yet, the earlier the antivenom is administered, the more effective it is in preventing serious complications such as necrosis, kidney failure, or coagulation disorders. However, in remote areas, stocks are often depleted, forcing patients to travel long distances to find treatment, further increasing the risks.

African health policies recognize the importance of antivenom serum and have included it in the lists of essential medicines. However, this recognition has not translated into improvements on the ground. Allocated budgets are insufficient, supply chains are failing, and unregulated prices in the private sector make the product inaccessible. Underfunded public hospitals cannot always maintain reserves, while private clinics sell it at exorbitant rates.

Distribution is another major issue. Antivenom is often concentrated in large urban hospitals, leaving small rural health centers—where the need is greatest—without resources. Logistics systems are poorly organized, demand forecasts are unreliable, and delays in tender processes worsen shortages. Additionally, the available antivenoms are not always suited to local snake species, as their production and approval are slow and poorly coordinated between countries.

The consequences are dramatic. Thousands of people die or are left with lifelong disabilities, even though solutions exist. Inequalities are widening: the poorest, who live far from cities and depend on agriculture, pay the highest price. Without affordable and accessible antivenom, snakebites continue to ruin lives, even though they should be a simple, solvable medical problem.

To change this, essential medicine policies need to be strengthened. This requires sustainable funding, better coordination of purchases between countries, and decentralized distribution to the most affected areas. It is also crucial to train local healthcare workers in managing snakebites and using antivenom. Finally, integrating case surveillance into health systems would allow stocks and resources to be adjusted based on actual needs.

Without these reforms, snakebites will remain a deadly threat to rural populations, even though they could be controlled.

Legal References

Reference Work

DOI: https://doi.org/10.1186/s12982-026-02316-z

Title: Strengthening essential medicines policy to improve antivenom availability and affordability for snakebite envenomation in rural sub-Saharan Africa

Journal: Discover Public Health

Publisher: Springer Science and Business Media LLC

Authors: Jonhas Masatu; Sadiki Kome; Helman Nyigo; Melkizedeki Abdulahi; Kassim Shellimoh; Emanuel Jonh; Jofrey Mtewele; William Paul; Daniel Amnaay; Emmanuela Marco; Joshua Karaba; David Osima; Majani Edward